Ngo L, Chan T, Ge J, Samson L, Engelward B. Microcolony Size Distribution Assay Enables High-Throughput Cell Survival Quantitation. Cell Rep. 2019;26:1668-1678.e4 pubmed publisher

Owusu M, Bannauer P, Ferreira da Silva J, Mourikis T, Jones A, Májek P, et al. Mapping the Human Kinome in Response to DNA Damage. Cell Rep. 2019;26:555-563.e6 pubmed publisher

Parry L, Young M, el Marjou F, Clarke A. Protocols for Analyzing the Role of Paneth Cells in Regenerating the Murine Intestine using Conditional Cre-lox Mouse Models. J Vis Exp. 2015;: pubmed publisher

Lollo G, Vincent M, Ullio Gamboa G, Lemaire L, Franconi F, Couez D, et al. Development of multifunctional lipid nanocapsules for the co-delivery of paclitaxel and CpG-ODN in the treatment of glioblastoma. Int J Pharm. 2015;495:972-80 pubmed publisher

Mohapatra P, Satapathy S, Siddharth S, Das D, Nayak A, Kundu C. Resveratrol and curcumin synergistically induces apoptosis in cigarette smoke condensate transformed breast epithelial cells through a p21(Waf1/Cip1) mediated inhibition of Hh-Gli signaling. Int J Biochem Cell Biol. 2015;66:75-84 pubmed publisher

Burri S, Prabhu R, Sumrall A, Brick W, Blaker B, Heideman B, et al. BCNU wafer placement with temozolomide (TMZ) in the immediate postoperative period after tumor resection followed by radiation therapy with TMZ in patients with newly diagnosed high grade glioma: final results of a prospective, multi-institutional, p. J Neurooncol. 2015;123:259-66 pubmed publisher

Gonsalves C, Eschelman D, Thornburg B, Frangos A, Sato T. Uveal Melanoma Metastatic to the Liver: Chemoembolization With 1,3-Bis-(2-Chloroethyl)-1-Nitrosourea. AJR Am J Roentgenol. 2015;205:429-33 pubmed publisher

Baxter P, Bell K, Hasel P, Kaindl A, Fricker M, Thomson D, et al. Synaptic NMDA receptor activity is coupled to the transcriptional control of the glutathione system. Nat Commun. 2015;6:6761 pubmed publisher

Sukumari Ramesh S, Prasad N, Alleyne C, Vender J, Dhandapani K. Overexpression of Nrf2 attenuates Carmustine-induced cytotoxicity in U87MG human glioma cells. BMC Cancer. 2015;15:118 pubmed publisher

Krishnamurthy N, Liu L, Xiong X, Zhang J, Montano M. Downregulation of hPMC2 imparts chemotherapeutic sensitivity to alkylating agents in breast cancer cells. Cancer Biol Ther. 2015;16:518-27 pubmed publisher

Olszko M, Adair J, Linde I, Rae D, Trobridge P, Hocum J, et al. Foamy viral vector integration sites in SCID-repopulating cells after MGMTP140K-mediated in vivo selection. Gene Ther. 2015;22:591-5 pubmed publisher

Kim J, Jin X, Ham S, Lee S, Seo S, Kim S, et al. IRF7 promotes glioma cell invasion by inhibiting AGO2 expression. Tumour Biol. 2015;36:5561-9 pubmed publisher

Tamargo J, Caballero R, Delpón E. Cancer chemotherapy and cardiac arrhythmias: a review. Drug Saf. 2015;38:129-52 pubmed publisher

Fan C, Ting C, Chang Y, Wei K, Liu H, Yeh C. Drug-loaded bubbles with matched focused ultrasound excitation for concurrent blood-brain barrier opening and brain-tumor drug delivery. Acta Biomater. 2015;15:89-101 pubmed publisher

Kim E, Kim S, Jin X, Ham S, Kim J, Park J, et al. Epidermal growth factor receptor variant III renders glioma cancer cells less differentiated by JAGGED1. Tumour Biol. 2015;36:2921-8 pubmed publisher

Venur V, Peereboom D, Ahluwalia M. Current medical treatment of glioblastoma. Cancer Treat Res. 2015;163:103-15 pubmed publisher

Chai K, Wang C, Liaw H, Fang K, Yang C, Tzeng S. Downregulation of BRCA1-BRCA2-containing complex subunit 3 sensitizes glioma cells to temozolomide. Oncotarget. 2014;5:10901-15 pubmed

Kanamori M, Higa T, Sonoda Y, Murakami S, Dodo M, Kitamura H, et al. Activation of the NRF2 pathway and its impact on the prognosis of anaplastic glioma patients. Neuro Oncol. 2015;17:555-65 pubmed publisher

Sewing A, Caretti V, Lagerweij T, Schellen P, Jansen M, van Vuurden D, et al. Convection enhanced delivery of carmustine to the murine brainstem: a feasibility study. J Neurosci Methods. 2014;238:88-94 pubmed publisher

Agnihotri S, Burrell K, Buczkowicz P, Remke M, Golbourn B, Chornenkyy Y, et al. ATM regulates 3-methylpurine-DNA glycosylase and promotes therapeutic resistance to alkylating agents. Cancer Discov. 2014;4:1198-213 pubmed publisher

Zhao H, Thienpont B, Yesilyurt B, Moisse M, Reumers J, Coenegrachts L, et al. Mismatch repair deficiency endows tumors with a unique mutation signature and sensitivity to DNA double-strand breaks. elife. 2014;3:e02725 pubmed publisher

Ji W, Yang M, Praggastis A, Li Y, Zhou H, He Y, et al. Carbamoylating activity associated with the activation of the antitumor agent laromustine inhibits angiogenesis by inducing ASK1-dependent endothelial cell death. PLoS ONE. 2014;9:e103224 pubmed publisher

Rancea M, Will A, Borchmann P, Monsef I, Engert A, Skoetz N. Sixteenth biannual report of the Cochrane Haematological Malignancies Group: focus on Non-Hodgkin's lymphoma. J Natl Cancer Inst. 2014;106: pubmed publisher

Zhang J, Chen M, Zhang Y, Zhao L, Yan R, Dai K. Carmustine induces platelet apoptosis. Platelets. 2015;26:437-42 pubmed publisher

Phaltane R, Lachmann N, Brennig S, Ackermann M, Modlich U, Moritz T. Lentiviral MGMT(P140K)-mediated in vivo selection employing a ubiquitous chromatin opening element (A2UCOE) linked to a cellular promoter. Biomaterials. 2014;35:7204-13 pubmed publisher

Kim S, Rait A, Kim E, Pirollo K, Nishida M, Farkas N, et al. A nanoparticle carrying the p53 gene targets tumors including cancer stem cells, sensitizes glioblastoma to chemotherapy and improves survival. ACS Nano. 2014;8:5494-514 pubmed publisher

Fan C, Liu H, Ting C, Lee Y, Huang C, Ma Y, et al. Submicron-bubble-enhanced focused ultrasound for blood-brain barrier disruption and improved CNS drug delivery. PLoS ONE. 2014;9:e96327 pubmed publisher

Xie Q, Yan Y, Huang Z, Zhong X, Huang L. MicroRNA-221 targeting PI3-K/Akt signaling axis induces cell proliferation and BCNU resistance in human glioblastoma. Neuropathology. 2014;34:455-64 pubmed publisher

Shankar A, Hayward J, Kirkwood A, McCarthy K, Hewitt M, Morland B, et al. Treatment outcome in children and adolescents with relapsed Hodgkin lymphoma--results of the UK HD3 relapse treatment strategy. Br J Haematol. 2014;165:534-44 pubmed publisher

Olson J, Nayak L, Ormond D, Wen P, Kalkanis S. The role of cytotoxic chemotherapy in the management of progressive glioblastoma : a systematic review and evidence-based clinical practice guideline. J Neurooncol. 2014;118:501-55 pubmed publisher

Kolstad A, Laurell A, Jerkeman M, Grønbæk K, Elonen E, Räty R, et al. Nordic MCL3 study: 90Y-ibritumomab-tiuxetan added to BEAM/C in non-CR patients before transplant in mantle cell lymphoma. Blood. 2014;123:2953-9 pubmed publisher

Rasche L, Strifler S, Duell J, Rosenwald A, Buck A, Maeder U, et al. The lymphoma-like polychemotherapy regimen "Dexa-BEAM" in advanced and extramedullary multiple myeloma. Ann Hematol. 2014;93:1207-14 pubmed publisher

Shah R, Homapour B, Casselden E, Barr J, Grundy P, Brydon H. Delayed post-operative haemorrhage after carmustine wafer implantation: a case series from two UK centres. Br J Neurosurg. 2014;28:488-94 pubmed publisher

Aoki T, Yamada S. [II. Current status of BCNU stent in the brain for treatment of glioma]. Gan To Kagaku Ryoho. 2013;40:708-17 pubmed

Eroglu C, Kaynar L, Orhan O, Keklik M, Sahin C, Yildiz O, et al. Contribution of involved-field radiotherapy to survival in patients with relapsed or refractory Hodgkin lymphoma undergoing autologous stem cell transplantation. Am J Clin Oncol. 2015;38:68-73 pubmed publisher

Gutenberg A, Lumenta C, Braunsdorf W, Sabel M, Mehdorn H, Westphal M, et al. The combination of carmustine wafers and temozolomide for the treatment of malignant gliomas. A comprehensive review of the rationale and clinical experience. J Neurooncol. 2013;113:163-74 pubmed publisher

Mikesch J, Kuhlmann M, Demant A, Krug U, Thoennissen G, Schmidt E, et al. DexaBEAM versus ICE salvage regimen prior to autologous transplantation for relapsed or refractory aggressive peripheral T cell lymphoma: a retrospective evaluation of parallel patient cohorts of one center. Ann Hematol. 2013;92:1041-8 pubmed publisher

Rahmathulla G, Marko N, Weil R. Cerebral radiation necrosis: a review of the pathobiology, diagnosis and management considerations. J Clin Neurosci. 2013;20:485-502 pubmed publisher

Salmaggi A, Milanesi I, Silvani A, Gaviani P, Marchetti M, Fariselli L, et al. Prospective study of carmustine wafers in combination with 6-month metronomic temozolomide and radiation therapy in newly diagnosed glioblastoma: preliminary results. J Neurosurg. 2013;118:821-9 pubmed publisher

Dörner L, Mustafa A, Rohr A, Mehdorn H, Nabavi A. Growth pattern of tumor recurrence following bis-chloroethylnitrosourea (BCNU) wafer implantation in malignant glioma. J Clin Neurosci. 2013;20:429-34 pubmed publisher

Tseng Y, Liao J, Chen W, Kao Y, Liu S. Sustainable release of carmustine from biodegradable poly[((D,L))-lactide-co-glycolide] nanofibrous membranes in the cerebral cavity: in vitro and in vivo studies. Expert Opin Drug Deliv. 2013;10:879-88 pubmed publisher

Fan C, Ting C, Liu H, Huang C, Hsieh H, Yen T, et al. Antiangiogenic-targeting drug-loaded microbubbles combined with focused ultrasound for glioma treatment. Biomaterials. 2013;34:2142-55 pubmed publisher

Huang H, Cheng A, Lin C, Kuo S. Primary central nervous system diffuse large B cell lymphoma transformed from orbital mucosa-associated lymphoid tissue lymphoma: complete response to combined intrathecal and systemic rituximab. Ann Hematol. 2013;92:989-92 pubmed publisher

Olney K, Du J, van t Erve T, Witmer J, Sibenaller Z, Wagner B, et al. Inhibitors of hydroperoxide metabolism enhance ascorbate-induced cytotoxicity. Free Radic Res. 2013;47:154-63 pubmed publisher

Li J, Khot A, Burbury K. Acute kidney injury requiring dialysis following carmustine and etoposide during autologous stem cell transplantation. Chemotherapy. 2012;58:349-51 pubmed publisher

Crabtree M, Brixey R, Batchelor H, Hale A, Channon K. Integrated redox sensor and effector functions for tetrahydrobiopterin- and glutathionylation-dependent endothelial nitric-oxide synthase uncoupling. J Biol Chem. 2013;288:561-9 pubmed publisher

Yuan S, Wang F, Chen G, Zhang H, Feng L, Wang L, et al. Effective elimination of cancer stem cells by a novel drug combination strategy. Stem Cells. 2013;31:23-34 pubmed publisher

Safdar S, Payne C, Tu N, Taite L. Targeted nitric oxide delivery preferentially induces glioma cell chemosensitivity via altered p53 and O(6) -methylguanine-DNA methyltransferase activity. Biotechnol Bioeng. 2013;110:1211-20 pubmed publisher

Raguz S, Adams C, Masrour N, Rasul S, Papoutsoglou P, Hu Y, et al. Loss of O⁶-methylguanine-DNA methyltransferase confers collateral sensitivity to carmustine in topoisomerase II-mediated doxorubicin resistant triple negative breast cancer cells. Biochem Pharmacol. 2013;85:186-96 pubmed publisher

Watts C, Dunn L, Ashkan K, Jenkinson M, Smith P. Establishing the efficacy of Gliadel wafers: progress towards a Phase III trial. Acta Neurochir (Wien). 2013;155:61-2 pubmed publisher

Inverardi F, Chikhladze M, Donzelli A, Moroni R, Regondi M, Pennacchio P, et al. Cytoarchitectural, behavioural and neurophysiological dysfunctions in the BCNU-treated rat model of cortical dysplasia. Eur J Neurosci. 2013;37:150-62 pubmed publisher

Krüger P, Cooney J, Turner J. Iodine-131 rituximab radioimmunotherapy with BEAM conditioning and autologous stem cell transplant salvage therapy for relapsed/refractory aggressive non-Hodgkin lymphoma. Cancer Biother Radiopharm. 2012;27:552-60 pubmed publisher

Bruserud O, Reikvam H, Kittang A, Ahmed A, Tvedt T, Sjo M, et al. High-dose etoposide in allogeneic stem cell transplantation. Cancer Chemother Pharmacol. 2012;70:765-82 pubmed publisher

Maier P, Heckmann D, Spier I, Laufs S, Zucknick M, Allgayer H, et al. F2A sequence linking MGMT(P140K) and MDR1 in a bicistronic lentiviral vector enables efficient chemoprotection of haematopoietic stem cells. Cancer Gene Ther. 2012;19:802-10 pubmed publisher

Antunes I, Haisma H, Elsinga P, Di Gialleonardo V, van Waarde A, Willemsen A, et al. Induction of ?-glucuronidase release by cytostatic agents in small tumors. Mol Pharm. 2012;9:3277-85 pubmed publisher

Chamberlain M. Role for cytotoxic chemotherapy in patients with recurrent glioblastoma progressing on bevacizumab: a retrospective case series. Expert Rev Neurother. 2012;12:929-36 pubmed

Vose J, Bierman P, Loberiza F, Enke C, Hankins J, Bociek R, et al. Phase II trial of 131-Iodine tositumomab with high-dose chemotherapy and autologous stem cell transplantation for relapsed diffuse large B cell lymphoma. Biol Blood Marrow Transplant. 2013;19:123-8 pubmed publisher

He P, Fang L, Su Z. A sequential testing approach to detecting multiple change points in the proportional hazards model. Stat Med. 2013;32:1239-45 pubmed publisher

Preukschas M, Hagel C, Schulte A, Weber K, Lamszus K, Sievert H, et al. Expression of eukaryotic initiation factor 5A and hypusine forming enzymes in glioblastoma patient samples: implications for new targeted therapies. PLoS ONE. 2012;7:e43468 pubmed publisher

Ferreri A, Bruno Ventre M, Donadoni G, Cattaneo C, Fumagalli L, Foppoli M, et al. Safety and activity of a new intensive short-term chemoimmunotherapy in HIV-positive patients with Burkitt lymphoma. Br J Haematol. 2012;159:252-5 pubmed publisher

O Meara A, Halter J, Heim D, Gerull S, Bucher C, Passweg J, et al. Allogeneic stem cell transplantation for relapsed or refractory lymphoma after conditioning with BEAM/fludarabine/TBI. Biol Blood Marrow Transplant. 2013;19:82-6 pubmed publisher

Falahati R, Zhang J, Flebbe Rehwaldt L, Shi Y, Gerson S, Gaensler K. Chemoselection of allogeneic HSC after murine neonatal transplantation without myeloablation or post-transplant immunosuppression. Mol Ther. 2012;20:2180-9 pubmed publisher

Dixit S, Hingorani M, Achawal S, Scott I. The sequential use of carmustine wafers (Gliadel®) and post-operative radiotherapy with concomitant temozolomide followed by adjuvant temozolomide: a clinical review. Br J Neurosurg. 2011;25:459-69 pubmed publisher

Nagaiah G, Almubarak M, Khan M, Altaha R. Cerebrospinal fluid leak during treatment with bevacizumab and irinotecan after carmustine-impregnated wafers placement in patients with grade 2 oligodendroglioma and glioblastoma multiforme: report of two cases and review of literature. Cancer Invest. 2010;28:1048-53 pubmed publisher

Skretas G, Georgiou G. Simple genetic selection protocol for isolation of overexpressed genes that enhance accumulation of membrane-integrated human G protein-coupled receptors in Escherichia coli. Appl Environ Microbiol. 2010;76:5852-9 pubmed publisher

Blazeck J, Alper H. Systems metabolic engineering: genome-scale models and beyond. Biotechnol J. 2010;5:647-59 pubmed publisher

Arredondo S, Chen T, Riggs A, Gilbert H, Georgiou G. Role of dimerization in the catalytic properties of the Escherichia coli disulfide isomerase DsbC. J Biol Chem. 2009;284:23972-9 pubmed publisher

Sabel M, Giese A. Safety profile of carmustine wafers in malignant glioma: a review of controlled trials and a decade of clinical experience. Curr Med Res Opin. 2008;24:3239-57 pubmed

Lin S, Kleinberg L. Carmustine wafers: localized delivery of chemotherapeutic agents in CNS malignancies. Expert Rev Anticancer Ther. 2008;8:343-59 pubmed publisher

Garside R, Pitt M, Anderson R, Rogers G, Dyer M, Mealing S, et al. The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation. Health Technol Assess. 2007;11:iii-iv, ix-221 pubmed

Zackheim H. Topical carmustine (BCNU) in the treatment of mycosis fungoides. Dermatol Ther. 2003;16:299-302 pubmed

Fleming A, Saltzman W. Pharmacokinetics of the carmustine implant. Clin Pharmacokinet. 2002;41:403-19 pubmed

Becker K, Schirmer R. 1,3-Bis(2-chloroethyl)-1-nitrosourea as thiol-carbamoylating agent in biological systems. Methods Enzymol. 1995;251:173-88 pubmed

Weiss R, Issell B. The nitrosoureas: carmustine (BCNU) and lomustine (CCNU). Cancer Treat Rev. 1982;9:313-30 pubmed

Stahl W, Lenhardt S, Przybylski M, Eisenbrand G. Mechanism of glutathione-mediated DNA damage by the antineoplastic agent 1,3-bis(2-chloroethyl)-N-nitrosourea. Chem Res Toxicol. 1992;5:106-9 pubmed